irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by recurrent abdominal pain (≥1 day/week for 3 months), bloating, and altered bowel habits (diarrhea, constipation, or mixed) without detectable structural pathology. It represents a breakdown in gut-brain axis communication, involving visceral hypersensitivity, chronic low-grade inflammation, dysbiosis, and increased intestinal permeability—a diagnosis of exclusion requiring systematic ruling out of inflammatory bowel disease, Coeliac disease, and infectious causes.
Imagine a factory floor (your gut) with an oversensitive alarm system (visceral hypersensitivity), a damaged perimeter fence (leaky gut barrier), and a disgruntled workforce (dysbiotic microbiome). The security cameras (sensory neurons) are set on maximum sensitivity—they trigger alarms for minor disturbances that normal factories would ignore. Meanwhile, holes in the fence allow unauthorized visitors (bacterial fragments, food antigens) to enter restricted areas, prompting the security team (immune cells) to release low-level alarm signals continuously. The factory's conveyor belt (gut motility) becomes erratic—sometimes racing too fast (diarrhea), sometimes jamming completely (constipation)—because the control room (enteric nervous system) is receiving conflicting signals from both the oversensitive sensors and the stressed headquarters upstairs (central nervous system). The head office (brain) keeps calling down with stress alerts, making the factory floor workers even more reactive. This isn't a broken machine with visible damage—all the equipment looks intact on inspection (normal endoscopy)—but the communication systems, security protocols, and workforce coordination are fundamentally dysfunctional. Every production cycle becomes unpredictable and painful.
IBS pathophysiology involves seven interconnected mechanisms operating simultaneously:
1. Visceral Hypersensitivity Pathway:
- Enhanced peripheral sensitization: upregulation of TRPV1 and TRPA1 channels on gut afferents → increased response to mechanical distension and chemical stimuli
- Central sensitization: repeated nociceptive input → dorsal horn hyperexcitability → NMDA receptor phosphorylation → amplified pain signaling
- Descending facilitation dominates over inhibition: reduced serotonin (5-HT3) modulation from rostroventral medulla → heightened pain perception at periaqueductal gray and anterior cingulate cortex
2. Gut Motility Dysfunction:
- Serotonin dysregulation: 95% of body's 5-HT is in gut → altered synthesis by enterochromaffin cells → abnormal 5-HT3 and 5-HT4 receptor activation
- In IBS-D: excessive 5-HT release → rapid colonic transit → diarrhea
- In IBS-C: reduced 5-HT signaling → slow transit → constipation
- Disrupted migrating motor complex (MMC) → bacterial overgrowth risk
3. Chronic Low-Grade Inflammation:
4. Gut Barrier Dysfunction:
5. Dysbiosis:
6. Gut-Brain Axis Dysfunction:
- Bidirectional communication breakdown:
- CRH (corticotropin-releasing hormone) directly stimulates mast cell degranulation in gut mucosa
- Reduced vagal tone (low HRV) → impaired anti-inflammatory reflex → sustained immune activation
7. Neuroendocrine Signaling:
- Altered Substance P release from enteric neurons → mast cell activation → inflammation amplification
- Dysregulated neuropeptide balance: increased pro-nociceptive (Substance P, CGRP) vs. decreased anti-nociceptive mediators
- Hypothalamic dysfunction: chronic stress → hypothalamic inflammation → disrupted autonomic output to gut
graph TD
A[Stress/Trauma/Infection] --> B[HPA Axis Activation]
A --> C[Gut Barrier Damage]
B --> D["Elevated Cortisol + CRH"]
D --> E[Mast Cell Degranulation]
C --> F[Increased Permeability]
F --> G[LPS/Antigen Translocation]
G --> H["TLR4 → NF-κB Activation"]
H --> I["IL-6, TNF-α, IL-1β Release"]
I --> J[Low-Grade Inflammation]
E --> J
J --> K[Visceral Hypersensitivity]
J --> L[Enteric Nervous System Dysfunction]
L --> M[Serotonin Dysregulation]
M --> N[Motility Disturbance]
N --> O[Dysbiosis]
O --> F
K --> P[Central Sensitization]
P --> Q[Chronic Abdominal Pain]
B --> R[Vagal Withdrawal]
R --> J
style Q fill:#ffcccc
style J fill:#ffe6cc
IBS affects 10-15% of the population with 2:1 female predominance, making it the most common functional GI disorder encountered in clinical practice. This condition exemplifies evolutionary mismatch: our gut evolved in context of intermittent pathogen exposure, fiber-rich diets, and physical activity, but now faces chronic stress, processed foods, antibiotics, and sedentarism—creating persistent barrier dysfunction and immune dysregulation without genuine infection to resolve.
Diagnostic Approach:
Rome IV criteria require recurrent abdominal pain ≥1 day/week for 3 months, with ≥2 of: pain related to defecation, change in stool frequency, or change in stool appearance. Must exclude red flags (blood in stool, unintentional weight loss, family history of colorectal cancer, age >50 without screening). Calprotectin 50-200 μg/g represents diagnostic gray zone—too high for pure functional disorder, too low for IBD—suggesting mild inflammatory component requiring intervention.
Multi-System Treatment Approach:
- Gut barrier restoration: L-glutamine (5-10g/day), zinc carnosine (75-150mg), butyrate supplementation, collagen peptides
- Microbiome modulation: Low-FODMAP diet (reduces fermentable substrates that feed dysbiotic bacteria), targeted probiotics (Bifidobacterium infantis 35624, Lactobacillus plantarum 299v), avoid unnecessary antibiotics
- Inflammation control: omega-3s (EPA 2-3g/day), curcumin, quercetin, specialized pro-resolving mediators (SPMs)
- Visceral hypersensitivity: pain neuroscience education, mindfulness, gut-directed hypnotherapy (evidence-based: reduces symptom severity by 40-70%)
- Stress axis regulation: vagus nerve stimulation, breathwork, address adverse childhood experiences (ACEs) which triple IBS risk
- Motility normalization: ginger (IBS-C), peppermint oil (IBS-D), 5-HTP (serotonin precursor)
Comorbidity Patterns:
IBS strongly clusters with anxiety (50-60%), depression (30-40%), fibromyalgia (60% overlap), chronic fatigue syndrome—suggesting shared central sensitization mechanisms and dysfunctional stress response systems. These are not separate diseases but manifestations of systemic allostatic load—the selfish brain prioritizing energy for threat processing at expense of digestive function.
Evolutionary Context:
Post-infectious IBS represents appropriate immune vigilance gone wrong—the gut "remembers" pathogen exposure and maintains heightened defenses indefinitely, creating mismatch between ancestral acute-infection environment and modern chronic-stress environment where threats never fully resolve.
- Prevalence: 10-15% global population, 2:1 female:male ratio (hormonal modulation of visceral pain perception)
- Rome IV criteria: recurrent abdominal pain ≥1 day/week for 3 months + change in stool frequency/form
- Subtypes: IBS-D (diarrhea-predominant, 33%), IBS-C (constipation, 33%), IBS-M (mixed, 33%)
- Calprotectin thresholds: <50 μg/g normal, 50-200 μg/g gray zone (suggests IBS with mild inflammation), >200 μg/g likely IBD
- Post-infectious IBS: 10% incidence after bacterial gastroenteritis, persists >6 months in susceptible individuals
- Mast cell elevation: 15-35 cells/HPF in IBS vs. 3-5 in healthy controls—even with normal endoscopy
- Cytokine elevation: IL-6 3-8 pg/mL in IBS mucosa vs. <2 pg/mL controls (subclinical inflammation)
- Microbiome alterations: 30-40% reduction in Bifidobacterium, 50% reduction in F. prausnitzii (butyrate producer)
- ACE correlation: ≥4 adverse childhood experiences increases IBS risk 3-fold (permanent gut-brain axis reprogramming)
- Treatment response: Low-FODMAP diet effective in 50-70%, gut-directed hypnotherapy reduces symptoms 40-70%
- Serotonin concentration: 90% of body's 5-HT in gut; enterochromaffin cell density increased 30% in IBS-D
- Quality of life: IBS severity correlates with anxiety/depression severity (r=0.6-0.7), not with endoscopic findings
- calprotectin — 50-200 μg/g gray zone distinguishes IBS with inflammation from pure functional disorder
- Coeliac disease — must exclude before IBS diagnosis; overlapping symptoms but distinct pathophysiology (immune-mediated villous atrophy)
- gut-brain axis — bidirectional dysfunction central to pathogenesis; stress exacerbates via HPA activation and vagal withdrawal
- dysbiosis — reduced Lactobacillus/Bifidobacterium/F. prausnitzii; increased Enterobacteriaceae drives inflammation
- intestinal permeability — leaky gut allows LPS translocation → TLR4 activation → chronic immune stimulation
- visceral hypersensitivity — TRPV1/TRPA1 upregulation + central sensitization creates pain amplification
- serotonin — gut 5-HT dysregulation affects motility (5-HT3/5-HT4 receptors); 90% body serotonin is enteric
- mast cells — 3-7x elevation in mucosa; degranulation releases histamine, tryptase, TNF-α perpetuating inflammation
- Low-FODMAP diet — reduces fermentable substrates that exacerbate symptoms; effective in 50-70% when properly implemented
- stress — chronic HPA activation → CRH-mediated mast cell degranulation + barrier dysfunction
- chronic low-grade inflammation — IL-6, IL-1β, TNF-α elevation without structural damage; metaflammation pattern
- inflammatory bowel disease — must distinguish from IBS; IBD has structural damage, higher calprotectin (>200), requires immunosuppression
- anxiety — 50-60% comorbidity; shared central sensitization mechanisms and autonomic dysregulation
- depression — 30-40% comorbidity; serotonin dysregulation affects both mood and gut motility
- fibromyalgia — 60% overlap; suggests systemic central sensitization with gut manifestation as one symptom cluster
- chronic fatigue syndrome — frequent comorbidity; shared mitochondrial dysfunction and inflammatory drivers
- zonulin — upregulation disrupts tight junctions; biomarker for barrier dysfunction
- butyrate — reduced production from dysbiosis impairs colonocyte energy and barrier integrity
- adverse childhood experiences — ≥4 ACEs triple IBS risk; early-life stress permanently alters gut-brain axis
- HPA axis — chronic activation drives cortisol elevation, vagal withdrawal, and immune-gut dysfunction
- vagus nerve — reduced vagal tone (low HRV) impairs anti-inflammatory reflex and gut-brain communication
- allostatic load — IBS represents cumulative stress burden exceeding adaptive capacity
- microbiome — compositional alterations (reduced diversity, pathobiont expansion) maintain inflammation
- short-chain fatty acids — reduced SCFA production (especially butyrate) from dysbiosis weakens barrier
- TLR4 — activated by translocated LPS → NF-κB pathway → cytokine release
- NF-κB — master inflammatory transcription factor; perpetuates low-grade immune activation
- central sensitization — NMDA receptor phosphorylation in dorsal horn amplifies pain signaling
- Module 4 — Clinical Immunology (calprotectin interpretation, low-grade inflammation)
- Module 5 — Neuroendocrinology and Stress Physiology (gut-brain axis, HPA dysfunction, visceral hypersensitivity)